Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
141.81
-0.70 (-0.49%)
At close: May 8, 2026, 4:00 PM EDT
141.39
-0.42 (-0.30%)
After-hours: May 8, 2026, 7:55 PM EDT
Revolution Medicines Employees
Revolution Medicines had 883 employees as of December 31, 2025. The number of employees increased by 349 or 65.36% compared to the previous year.
Employees
883
Change (1Y)
349
Growth (1Y)
65.36%
Revenue / Employee
n/a
Profits / Employee
-$1,553,455
Market Cap
30.15B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 883 | 349 | 65.36% |
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
RVMD News
- 3 days ago - Revolution Medicines price target raised to $185 from $170 at BofA - TheFly
- 3 days ago - Revolution Medicines price target raised to $172 from $120 at Piper Sandler - TheFly
- 3 days ago - Revolution Medicines price target raised to $205 from $175 at Guggenheim - TheFly
- 3 days ago - Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84) - TheFly
- 3 days ago - Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B - TheFly
- 3 days ago - Revolution Medicines announces NEJM publication of data on Daraxonrasib - TheFly
- 3 days ago - Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer - GlobeNewsWire
- 3 days ago - Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects - Reuters